44th Annual J.P. Morgan Healthcare Conference in San Francisco

We're kicking off 2026 in San Francisco! Our CEO Jan Thirkettle will be in the city next week during the 44th Annual J.P. Morgan Healthcare Conference, connecting with life science leaders and investors.

Jan will be sharing the latest on our MISBA® platform technology for controlled protein modulation, and our broad neurodegenerative pipeline, including our lead Huntington's disease programme targeting FAN1.

hashtag#JPMorganHealthcareConference hashtag#HarnessTherapeutics hashtag#MISBA hashtag#HuntingtonsDisease hashtag#NeurodegenerativeDiseases

Our programmes

Huntington's Disease

Discover more

ALS and Alzheimer's

Discover more

Our news

February 2026

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board

October 2025

Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment

June 2025

Harness Therapeutics Publishes HTT CAG Repeat Sizing Methodology Code on GitHub

February 2025

Harness Therapeutics to Present Nanopore Sequencing Data for Detecting CAG Expansion in the Huntingtin Gene at CHDI Huntington’s Disease Therapeutics Conference

View all